Nuformix PLC Resignation of Auditor (5200I)

TIDMNFX

RNS Number : 5200I

Nuformix PLC

05 December 2022

5 December 2022

Nuformix plc

("Nuformix" or the "Company")

Resignation of Auditor

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the resignation of Jeffreys Henry LLP ("Jeffreys Henry") as auditors to the Company. Section 519 of the Companies Act 2006 (the "Act") requires Jeffreys Henry to send a statement of the reasons for ceasing to hold office. They have stated that in accordance with Section 519 of the Act, they are ceasing to hold office due to the following reason:

"Jeffreys Henry LLP have resigned as auditor on the grounds that the firm has taken the decision not to register as an auditor eligible to undertake Public Interest Entity audits."

There are no circumstances connected with Jeffreys Henry ceasing to hold office as auditor which they consider should be brought to the attention of the Company's members or creditors. As required by the Companies Act, Nuformix will send a copy of the resignation letter to shareholders.

The appointment of a new auditor will be announced in due course following the completion of a tender process.

Enquiries:

 
 Nuformix plc 
 Dr Julian Gilbert, Non-executive           Via IFC Advisory 
  Chairman 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  +44 (0) 20 3650 3650 
 John Howes (Corporate Broking)             +44 (0) 20 3650 3652 
 IFC Advisory Limited 
 Tim Metcalfe                               +44 (0) 20 3934 6630 
  Zach Cohen                                 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPFLFSTFLLSIIF

(END) Dow Jones Newswires

December 05, 2022 02:00 ET (07:00 GMT)

Nuformix (LSE:NFX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024